Compare ZLAB & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZLAB | IMNM |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.6B |
| IPO Year | 2017 | 2020 |
| Metric | ZLAB | IMNM |
|---|---|---|
| Price | $18.57 | $22.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $49.60 | $32.80 |
| AVG Volume (30 Days) | 640.0K | ★ 910.6K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 38.46 | ★ 51.40 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $460,156,000.00 | $6,941,000.00 |
| Revenue This Year | $9.75 | N/A |
| Revenue Next Year | $26.03 | $1,127.34 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.33 | N/A |
| 52 Week Low | $15.96 | $7.96 |
| 52 Week High | $44.34 | $27.65 |
| Indicator | ZLAB | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 41.21 | 52.61 |
| Support Level | $16.88 | $19.28 |
| Resistance Level | $19.64 | $23.24 |
| Average True Range (ATR) | 0.87 | 1.21 |
| MACD | -0.14 | 0.05 |
| Stochastic Oscillator | 22.67 | 68.72 |
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.